The EPS and revenue beats are largely non-recurring (milestone-driven). Focus shifts to Q1 2027 catalysts: SONATA-HCM topline and ZYNQUISTA NDA resubmission. Cash runway appears sufficient through these events.
Drugs in focus
LXRX drug pipeline →ZYNQUISTA
◆ Mixed Named in this press release- Impact
- Phase
- Filed/Pre-NDA resubmission (already approved as Inpefa for heart failure)
- Time to market
- Uncertain. NDA resubmission expected Q4 2026; if accepted, FDA has up to 6 months to review a Class 2 resubmission, meaning a potential decision in mid-2027 at the earliest.
- Next catalyst
- None dated
What to watchWatch for Zynquista NDA resubmission announcement in Q4 2026, that event will signal whether Lexicon believes it has adequately addressed FDA concerns. Success would be a major de-risking event; failure or further delay would be a severe blow given the company's pipeline reliance on sotagliflozin. The ~41.6% implied upside to the analyst mean price target reflects the binary nature of this catalyst.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 5 $1.61entry
- T+1 · 11d ago +10.56%α +10.25% · $1.78
- T+5 · 5d ago +13.04%α +9.75% · $1.82
- T+7 · todayOpen
- T+20 · in 17d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Lexicon reported Q3 2026 net loss of $0.03 per share, narrower than the consensus estimate of -$0.05, on total revenue of $11.3M (including a $10M milestone from Novo), above the $4.1M consensus. The beat was driven by the milestone payment, not product sales; the company highlighted completion of SONATA-HCM enrollment and plans to resubmit the ZYNQUISTA NDA in Q1 2027.
Key Financial Metrics
Key Facts
- Net loss per share -$0.03 vs consensus -$0.05 (beat)
- Total revenue $11.3M vs consensus $4.1M (beat), driven by $10M Novo milestone
- INPEFA net product revenue $1.2M, up from $1.0M YoY
- Cash and investments $183.2M as of Sep 30, 2026, up from $125.2M at Dec 31, 2025
- SONATA-HCM Phase 3 study enrolled 542 patients, top-line data expected Q1 2027
- ZYNQUISTA NDA resubmission anticipated Q1 2027 after positive STENO1 safety data
- LX9851 Phase 1 ongoing by Novo; Lexicon earned $75M of potential $1B milestones
Financial Impact
Net loss per share -$0.03 beat consensus by $0.02; revenue beat by $7.2M due to milestone
Risk Factors
- Revenue beat is non-recurring milestone; product revenue remains modest
- SONATA-HCM topline data in Q1 2027 is binary and could disappoint
- ZYNQUISTA NDA resubmission outcome uncertain; FDA could request additional data
- Operating losses continue; cash burn rate requires monitoring
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3396236 |
Track record
16 reports on LXRX
4 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +27.52% at T+20 after the Sep 22, 2026 report. 4 of 5 went positive at some point.
Filters
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $1.61 to $1.78 Now $1.75 +8.70% ▲ +10.56% +10.25% vs SPY
- Nov 5, 202611d ago 8-K Neutral 4/10 No price data
- Nov 5, 202611d ago Press Release Neutral 4/10 Viewing Entry $1.61 to $1.78 Now $1.75 +8.70% ▲ +10.56% +10.25% vs SPY
- Sep 22, 20267w ago Institutional Cluster Bearish 4/10 Entry $2.18 to $2.06 Now $1.75 +19.72% ▲ +5.50% +4.78% vs SPY
- Aug 6, 202614w ago 8-K Neutral 5/10 No price data
- Aug 6, 202614w ago Press Release Neutral 5/10 Entry $2.36 to $2.47 Now $1.75 −25.85% ▲ +4.66% +4.05% vs SPY
- Jun 12, 202622w ago Institutional Cluster Bearish 5/10 Entry $1.92 to $1.96 Now $1.75 +8.85% ▼ −2.08% −0.32% vs SPY
- Jun 11, 202622w ago Institutional Cluster Neutral 2/10 Entry $1.89 to $1.92 Now $1.75 −7.41% ▲ +1.59% +1.05% vs SPY
- May 6, 202627w ago 8-K Neutral 4/10 Entry $1.68 to $1.68 Now $1.75 +4.17% · 0.00% −0.83% vs SPY
- Apr 30, 202628w ago 8-K Bearish 6/10 Entry $1.63 to $1.60 Now $1.75 −7.36% ▲ +1.84% +1.50% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers